What a recurrence score changes about treatment

For a long time, a large group of women with early breast cancer were offered chemotherapy after surgery because there was no reliable way to tell who actually needed it. Some of them benefited. Many of them did not, and went through the side effects anyway.

That is the gap a recurrence score is meant to fill. It uses a tumour sample to estimate how likely the cancer is to come back, and from that, how much chemotherapy is likely to add.

The score is not measuring how bad your cancer is. It is estimating how much a particular treatment would help.

The National Cancer Institute describes TAILORx as a study examining whether a molecular profiling test could identify which early-stage breast cancer patients truly need chemotherapy.

Women were grouped by their test result, and treatment was compared within those groups. The findings NCI reports are specific.

Low-risk group. At five years, rates of distant relapse-free survival were 99.3% with hormone therapy alone. NCI's reading is that these patients do not require chemotherapy.

Intermediate-risk group. Adjuvant hormone therapy alone worked as well as hormone therapy and chemotherapy together. After nine years of follow-up, the rates of invasive disease-free survival were 83.3% for hormone therapy alone and 84.3% for hormone therapy and chemotherapy.

NCI summarises the practical consequence: rather than giving all early-stage breast cancer patients chemotherapy, the trial demonstrated that a molecular profiling test identifies women with a low risk of recurrence who can be spared chemotherapy, allowing treatment to be personalised based on individual risk.

It does not mean spared treatment. In every group described above, hormone therapy was part of the plan. The question the trial answered was about adding chemotherapy on top, not about doing nothing.

It also does not mean the score decides on its own. Your cancer's size, its other features, your age and your own view of the trade-offs all belong in the conversation. A test result is evidence brought into a decision — it is not the decision.

Recurrence scores describe likelihood across groups of people. They cannot tell any individual what will happen to them, and it is worth being honest with yourself about that when you receive one.

A low score does not promise safety and a higher one does not promise trouble. What a score does is let you and your oncologist reason about a real choice with better information than a coin toss.

Some people find that clarifying. Others find the probabilistic framing hard to sit with, particularly when they had hoped for a definite answer. Both reactions are normal, and it is worth telling your team which one you are having, because it changes how they should talk you through the options.

The most useful thing you can do with a score is turn it into a comparison. Ask your oncologist to walk you through what they would recommend with the result, and what they would have recommended without it. If the answer is the same either way, that is useful to know. If it is different, you learn exactly what work the test is doing.

Then ask about the trade-offs on both sides — what chemotherapy would involve for you, and what the plan without it looks like, including follow-up.

The point of a recurrence score is to make a hard decision more informed. That only happens if the information actually reaches you in a form you can use.